MIAMI, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
ANAHEIM, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...
PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage...
- Stride velocity 95th centile (SV95C) data demonstrate improvements at one-year post-dosing compared with declines observed in control and natural...
Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and...
Topline results for PATHFNDR-1 study expected in Q3 2023SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:...
BOTHELL, Wash., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-interim CEO Sam...
- Q3 2022 Consolidated Revenue Growth of 17% to $20.8 million - Q3 2022 North American Revenue Growth of 19%...
Higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baselineLack of activity compared to 0.3 mg...
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations,...
Company Spotlights its Appreciation to Physical Therapists Trained in its Innovative PoNS Therapy™ in Honor of National Physical Therapy MonthNEWTOWN,...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 13, 2022...
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform,...
Study provides support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trialsBOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE)...
• Treatment with apraglutide resulted in an average 50% reduction in Parenteral Support (PS) volume at six months • 80% of...
Sera collected from participants 7 days after administration of a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine...
Studies in non-human primates demonstrated nearly 100% gene editing and knockout of endogenous RHO gene and more than 30% replacement...
Highlights: Immuron has signed a subscription and option agreement with leading gut health biotech Ateria Health: Strategic investment of approximately...
First presentation of ERADICATE phase 3 study dataStudy met its primary and secondary endpoints comparing ceftobiprole versus daptomycin with or...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 13, 2022...